- Translational Research Fellowship
- Clinical Research Fellowship
Training Experience required
All clinical research fellows must have:
- Medical degree from a recognised institution
- Full GMC registration
- Clinical experience relevant to the post
- Research experience relevant to the project
General description of the institute
Barts Health NHS Trust is one of Britain's leading healthcare providers and the largest trust in the NHS. It was created in 2012 by bringing together three trusts: Barts and The London NHS Trust, Newham University Hospital NHS Trust and Whipps Cross University Hospital NHS Trust. The new trust has a turnover of approximately £1.1 billion and approximately 15,000 employees.
Together our hospitals - Newham University Hospital in Plaistow, St Bartholomew's (Barts) in the City, The Royal London in Whitechapel, The London Chest in Bethnal Green and Whipps Cross in Leytonstone - deliver high quality clinical care to the people of east London and further afield.
The hospitals offer a full portfolio of services that serve the needs of the local community, and are home to some of Britain's leading specialist centres including cancer, cardiac, trauma and emergency care. Barts Health also has one of the UK's busiest children's hospitals and internationally renowned surgical facilities.
Barts Health's vision is to create a world-class health organisation that builds on strong relations with our partners and the communities we serve - one dedicated to ending the historic health inequalities in east London. We will build an international reputation for excellence in patient care, research and education.
As members of UCL Partners, the largest academic health sciences system in the world, we will ensure that our patients are some of the first in the country to benefit from the latest drugs and treatments.
Barts Cancer Institute (BCI) is a major international centre of excellence in pre-clinical, translational and clinical cancer research, fully integrated into the care of patients at Barts Health NHS Trust. The Institute was placed 3rd overall in the country for the proportion of activity (85%) at the highest 4* (world-leading) and 3* (internationally excellent) categories in the 2008 RAE. The Institute's research strategy is built on an integrated molecular and cellular approach to cancer in individuals and in populations through integrated basic, translational and clinical programmes. The scientific focus includes development of novel molecular approaches for diagnosis, classification and treatment with the overarching goal of working towards personalised, targeted treatment.
There is particular expertise in five disease areas - haemato-oncology, women's (breast and gynaecological), lung, upper GI and urological cancers.
In addition, Immunetherapy is one of the main areas of clinical and scientifc expertise at Barts Cancer Institute. Immunotherapy represents one of the most promising and rapidly developing new cancer treatment approaches and Barts Cancer Institute and Barts Hospital have been at the forefront of this development. Professor Peter Schmid and Professor Tom Powles lead the cancer immunotherapy group at Barts which oversees a significant clinical and translational research programme on immune checkpoint inhibitors and other immune strategies.
please refer to http://www.bci.qmul.ac.uk and/or http://www.bartshealth.nhs.uk/our-hospitals/st-bartholomew's-hospital